Company Overview
Company Type: Public Company
Website: hemostemix.com
Number of Employees: -
Ticker: HEM (TSXV)
Year Founded: -


Business Description
Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions. The company develops cell therapy products from the patient’s own blood, which is a non-invasive source of therapeutic cells. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia in Canada and the United States. The company is also developing various types of cell products, such as synergetic cell populations, neural cell precursors, and cardiomyocyte cell precursors. Hemostemix Inc. is headquartered in Calgary, Canada.

Financial Information (Currency: CAD, in mm) 
Market Capitalization
10.0
EBITDA
(3.0)
Total Enterprise Value
14.1
TEV/EBITDA
NM
EBIT
(3.1)
Cash & ST Invst.
0.2
P/Diluted EPS Before Extra
NM
Net Income
(3.7)
Total Debt
4.2
Price/Tang BV
NM
Total Assets
0.3
Total Debt/EBITDA
NM
Currency in CAD in mm, LTM as of Jun-30-2023 TEV and Market Cap are calculated using a close price as of Oct-06-2023

Key Professionals
Name
Title
Smeenk, Thomas A.
Co-Founder, President, CEO & Director
Wu, Christina 
Interim Chief Financial Officer
Pavlin, Peter 
Vice President of Operations
Henderson, Fraser C.
Chief Medical Officer

Key Board Members
Name
Title
Lacey, Peter Alan
Independent Chairman
Smeenk, Thomas A.
Co-Founder, President, CEO & Director
Hershman, Ronnie Allen
Independent Director
Cecere, Renzo 
Member of Scientific Advisory Board
Copps, Sheila 
Member of Board of Advisors
Giannetti, Nadia 
Member of Scientific Advisory Board
Grillari, Johannes 
Scientific Advisory Board
Hari, Kumar L.
Member of Scientific Advisory Board
Hebert, Terry 
Member of Scientific Advisory Board
Hsiang, York N.
Member of Scientific Advisory Board
Lumsden, Alan B.
Member of Scientific Advisory Board
Swanberg, Loran 
Independent Director


Primary Industry Classification
Biotechnology


Primary Office Location
707-7th Avenue SW Suite 1150 | Calgary, AB | T2P 3H6 | Canada

Current and Pending Investors
Wood Capital Ltd., Zenith Appraisal & Land Consulting Ltd.

Prior Investors
Drive Capital Corporation

Stock Quote and Chart (Currency: CAD)
Last  (Delayed)
 0.12
Market Cap (mm)
10.0
Open
 0.12
Shares Out. (mm)
87.1
Previous Close
 0.12
Float %
85.3%
Change on Day
0.00
Shares Sold Short (mm)
-
Change % on Day
0.0%
Dividend Yield %
-
Day High/Low
 0.12/ 0.11
Diluted EPS Excl. Extra Items
(0.05)
52 wk High/Low
 0.28/ 0.10
P/Diluted EPS Before Extra
NM
Volume (mm)
0.03
Avg 3M Dly Vlm (mm)
0.04
Beta 5Y
0.62


 
Delayed Quote** | Last Updated on Oct-06-2023 12:00 AM (GMT-5)
TSXV:HEM - Common Stock


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
Technical Ventures RX Corp.
As of November 10, 2014, Technical Ventures RX Corp was acquired by TheraVitae Inc in a reverse merger transaction. Technical Ventures RX Corp. is a capital pool company. The company was founded in 2012 and is based in Surrey, Canada.

United States and Canada
Asset Management and Custody Banks
-
0.00
0.00
PreCerv Inc.
PreCerv Inc. develops autologous stem cell technologies to treat conditions of the central and peripheral nervous system. The company is based in Canada. PreCerv Inc. operates as a subsidiary of Hemostemix Inc.

United States and Canada
Biotechnology
-
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Sep-28-2023
-
Private Placement
Target
Hemostemix Inc. (TSXV:HEM)


0.24
Jun-01-2023
Sep-27-2023
Private Placement
Target
Hemostemix Inc. (TSXV:HEM)


0.54
Mar-07-2023
-
Private Placement
Target
Hemostemix Inc. (TSXV:HEM)


17.50
Feb-01-2023
Mar-21-2023
Private Placement
Target
Hemostemix Inc. (TSXV:HEM)


0.56
Aug-31-2022
-
Spin-Off/Split-Off
Seller
PreCerv Inc.

Hemostemix Inc. (TSXV:HEM)
-
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Sep-28-2023
Private Placements
Hemostemix Inc. announced that it expects to receive CAD 0.325125 million in funding
Sep-27-2023
Private Placements
Hemostemix Inc. announced that it has received CAD 0.72754 million in funding
Sep-15-2023
Product-Related Announcements
Hemostemix Inc. Announces Its Study of NCP-01 Supporting Brain Computer Interfaces Has Been Submitted for Peer Review Publication
Aug-10-2023
Product-Related Announcements
Hemostemix Inc. Submits its Retrospective Heart Study to Leading Stem Cell Journal
Jun-09-2023
Annual General Meeting
Hemostemix Inc., Annual General Meeting, Jun 09, 2023


Advisors
Most Recent Auditor
MNP LLP
Private Placement Advisors
Canaccord Genuity Group Inc. (TSX:CF), Fidelity Clearing Canada ULC, PI Financial Corp., Research Capital Corporation, Wolverton Securities Ltd
Public Offering Advisors
PI Financial Corp.


Most Recent Auditor
Meyers Norris Penny LLP - MNP LLP


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
S&P Global Compustat

Oct 05, 2023 03:58 AM
HEM
Hemostemix Inc 2023_10_05
Reports
14
GlobalData

Sep 15, 2023 08:08 AM
HEM
Hemostemix Inc (HEM.CVE) - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
82
GlobalData

Sep 13, 2023 02:21 AM
HEM
Hemostemix Inc (HEM.CVE) - Financial Analysis Review
Reports
195
S&P Global Compustat

Sep 07, 2023 03:55 AM
HEM
Hemostemix Inc 2023_09_07
Reports
14
GlobalData

Aug 29, 2023 01:54 AM
HEM
Hemostemix Inc (HEM.CVE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
60
S&P Global Compustat

Jul 06, 2023 03:27 AM
HEM
Hemostemix Inc 2023_07_06
Reports
14
GlobalData

Jun 09, 2023 05:00 AM
HEM
Hemostemix Inc (HEM.CVE) - Financial Analysis Review
Reports
193
GlobalData

Jun 08, 2023 11:44 PM
HEM
Hemostemix Inc (HEM.CVE) - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
84
Smart Insider Ltd.

Jun 07, 2023 03:13 AM
HEM
Hemnet Group AB: 1 director
Reporting Results*
1
S&P Global Compustat

Jun 01, 2023 04:21 AM
HEM
Hemostemix Inc 2023_06_01
Reports
14


Ownership Summary

            Top Holders 
Holders by Type
Holder

Common Stock Equivalent Held

% of Total Shares Outstanding

Market Value (CAD in mm)

Position Date


Lacey, Peter Alan

6,096,214

7.00

0.7

Apr-20-2023


Swanberg, Loran 

4,486,445

5.15

0.5

Jun-27-2023


Smeenk B.A., BA Hons, Thomas A.

1,492,593

1.71

0.2

Aug-03-2023


Hershman M.D., Ronnie Allen

566,257

0.65

0.1

Apr-20-2023


Summerhill Investment Corp

150,000

0.17

0.0

Apr-20-2023



 



Top Buyers
Buyers
Common Stock Equivalent Held
Change
Swanberg, Loran 
4,486,445
1,250,000
Smeenk B.A., BA Hons, Thomas A.
1,492,593
29,234

Top Sellers
Sellers
Common Stock Equivalent Held
Change
Lacey, Peter Alan
6,096,214
(3,639)


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
ACP-01 (Future)


Upcoming Events
Date/Time
Type
Nov-29-2023
Estimated Earnings Release Date (S&P Global Derived)
* Future Events are subject to change.


Recent Major Filings

Key Filings
Filed On
Period Date
Company Name
Source
Form Type
Size
Oct-03-2023
-
Hemostemix Inc. (TSXV:HEM)
SEDAR
News Releases
33 KB
Oct-03-2023
-
Hemostemix Inc. (TSXV:HEM)
SEDAR
News Releases
35 KB
Sep-15-2023
-
Hemostemix Inc. (TSXV:HEM)
SEDAR
News Releases
34 KB
Aug-29-2023
Jun-30-2023
Hemostemix Inc. (TSXV:HEM)
SEDAR
Interim Financial Statements
257 KB
Aug-29-2023
-
Hemostemix Inc. (TSXV:HEM)
SEDAR
News Releases
32 KB
Aug-14-2023
-
Hemostemix Inc. (TSXV:HEM)
SEDAR
News Releases
32 KB
Aug-10-2023
-
Hemostemix Inc. (TSXV:HEM)
SEDAR
News Releases
211 KB
Jul-04-2023
-
Hemostemix Inc. (TSXV:HEM)
SEDAR
News Releases
36 KB
Jun-22-2023
-
Hemostemix Inc. (TSXV:HEM)
SEDAR
News Releases
36 KB
May-29-2023
Mar-31-2023
Hemostemix Inc. (TSXV:HEM)
SEDAR
Interim Financial Statements
233 KB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
Smeenk B.A., BA Hons, Thomas A. (Co-Founder, President, CEO & Director)
Aug-03-2023
Common Shares
29,234
-
Other Acquisition
2.00
Multiple
Swanberg, Loran  (Independent Director)
Jun-27-2023
Common Shares
1,250,000
155,734
Acquisition Under Employee Benefit Plan
38.62
Multiple
Smeenk B.A., BA Hons, Thomas A. (Co-Founder, President, CEO & Director)
May-03-2023
Common Shares
4,000
603
Open Market Acquisition
0.27
Multiple
Smeenk B.A., BA Hons, Thomas A. (Co-Founder, President, CEO & Director)
Apr-14-2023
Common Shares
4,000
655
Open Market Acquisition
0.27
Multiple
Smeenk B.A., BA Hons, Thomas A. (Co-Founder, President, CEO & Director)
Apr-06-2023
Common Shares
30,000
4,489
Open Market Acquisition
2.10
Multiple
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
Lacey, Peter Alan
Independent Chairman
-
-

Smeenk, Thomas A.
Co-Founder, President, CEO & Director
905-580-4170
-
TSmeenk@Hemostemix.com
Hershman, Ronnie Allen
Independent Director
-
-

Cecere, Renzo 
Member of Scientific Advisory Board
-
-

Copps, Sheila 
Member of Board of Advisors
-
-

Giannetti, Nadia 
Member of Scientific Advisory Board
-
-

Grillari, Johannes 
Scientific Advisory Board
-
-

Hari, Kumar L.
Member of Scientific Advisory Board
-
-

Hebert, Terry 
Member of Scientific Advisory Board
-
-

Hsiang, York N.
Member of Scientific Advisory Board
-
-
-
Lumsden, Alan B.
Member of Scientific Advisory Board
-
-

Swanberg, Loran 
Independent Director
-
-

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Smeenk, Thomas A.
Co-Founder, President, CEO & Director
905-580-4170
-
TSmeenk@Hemostemix.com
Wu, Christina 
Interim Chief Financial Officer
-
-

Pavlin, Peter 
Vice President of Operations
-
-

Henderson, Fraser C.
Chief Medical Officer
-
-

* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 

**Intraday Quotes are delayed by at least 20 minutes.
